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High-throughput screening (HTS) of chemical librar-
ies has become a critical tool in basic biology and
drug discovery. However, its implementation and
the adaptation of high-content assays to human
embryonic stem cells (hESCs) have been hampered
by multiple technical challenges. Here we present
a strategy to adapt hESCs to HTS conditions, result-
ing in an assay suitable for the discovery of smallmol-
ecules that drive hESC self-renewal or differentiation.
Use of this new assay has led to the identification of
several marketed drugs and natural compounds pro-
moting short-term hESC maintenance and com-
poundsdirecting early lineage choice duringdifferen-
tiation. Global gene expression analysis upon drug
treatment defines known and novel pathways corre-
lated to hESC self-renewal and differentiation. Our
results demonstrate feasibility of hESC-based HTS
and enhance the repertoire of chemical compounds
for manipulating hESC fate. The availability of high-
content assays should accelerate progress in basic
and translational hESC biology.
INTRODUCTION
The availability of libraries of chemical compounds is a critical
tool in drug discovery. High-throughput chemical screens have
also become an important strategy to address questions in basic
biology including stem cell research (Ding and Schultz, 2004).
Recent studies have identified novel small molecules that medi-
ate cell-fate acquisition and the differentiation behavior of a num-
ber of stem cell types. Examples include the following: self-
renewal in mouse ES cells via dual inhibition of RasGAP and
ERK1(Chen et al., 2006), neural (Ding et al., 2003) or cardiogenic
(Wu et al., 2004a) specification of mouse ESCs, neurogenic
response of neural stem/precursor cells by an orphan ligand,
P-Ser (Saxe et al., 2007), or osteogenic differentiation in mesen-602 Cell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc.chymal stem in response to purmorphamine (Wu et al., 2004b).
Results from primary screens in mouse cells may often be appli-
cable to similar cell populations of human origin. However, in the
case of human ESCs (hESCs), this may not be the case given the
distinct extrinsic signaling requirements to retain pluripotency in
mouse (Ying et al., 2003) versus human (Vallier et al., 2005) ESCs.
hESCs self-renew extensively and give rise to various special-
ized cells relevant for modeling human development and for ap-
plications in regenerative medicine. While key transcription fac-
tors important for hESC renewal such as Oct4, Nanog, and Sox2
have been well characterized (Boyer et al., 2005; Ginis et al.,
2004; Sato et al., 2003), extrinsic factors regulating hESC main-
tenance and early differentiation events are poorly understood
(Hoffman and Carpenter, 2005). The development of high-
content assays in hESCs has been challenging due to the diffi-
culties in establishing suitable growth and plating conditions.
Here we report the first HTS assay in hESCs and identify mole-
cules that promote short-term self-renewal or drive early differ-
entiation. Our data pave the way for the routine application of
HTS assays in hESC biology and expand the repertoire of com-
pounds available for manipulating hESC fate.
RESULTS
Adapting hESC Culture Conditions for HTS Platform
A critical step in the development of a robust hESC-based assay is
the reproducible behavior of large-scale hESC cultures in a multi-
well format. Prior to seeding in 384-well plates, hESCs were
maintained under feeder-free conditions (Xu et al., 2001) and as-
sessed for the expression of pluripotency markers (Figure 1A,
see Figure S1 available online). To assure uniform cell distribution,
we developed a single-cell dissociation protocol for hESCs by
testing various enzymatic treatments and plating strategies
(Figure S2). Accutase treatment resulted in fully dissociated cells
suitable for plating on Matrigel-coated 384-well plates. Under
these conditions, we observed a robust cell-density-dependent
growth response as measured by Alamar blue at day 7 (Antczak
et al., 2007; O’Brien et al., 2000) (Figure 1B). Plating of 6000 cells
per well led to a density of hESCs suitable for automated micros-
copy and image analysis at 7 days after plating. At the time of
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(A) HESCs (H9 line) maintained on Matrigel prior to 384-well plating exhibit typical undifferentiated cell morphology (phase contrast), express Oct4, and incor-
porate the S phase marker BrdU.
(B) Cell titration on Matrigel-coated 384-well plates followed Alamar blue assay to determine the number of metabolically active cells (relative fluorescence
units, RFU). Data are presented as mean ± SEM. Cell density refers to seeding density at the time of plating; Alamar blue is added at day 7, RFU is measured
at day 8.
(C) (Upper panel) Quantification of Oct4 signal after treatment of hESCs in 384-well plates with BMP4 (low control) and FGF2 (high control). (Lower panel)
Corresponding immunocytochemical analysis for Oct4 and Nanog in BMP4 and FGF2-treated cells. AU corresponds to arbitrary units. Data are presented
as mean ± SEM.
(D) Schematic representation of HTS assay: undifferentiated hESCs were grown on Matrigel, dissociated into single cells using Accutase, and plated onto
Matrigel-coated 384-well plates at a density of 6000 cells per well. After 48 hr, compounds (yellow) and high and low controls (red, FGF2; green, BMP4)
were added for an additional 5 days. At day 7, automated immunocytochemistry for Oct4 was performed and signal intensity was quantified using automated
laser-scanning confocal microscopy (GE InCell Analyzer 3000). The specific image shown corresponds to a culture well at day 7 after plating maintained in the
presence of FGF2.
(E) Control experiments in HTS conditions were carried out using IGF2 for similar effect as FGF2 and BMP2 and PD98059 for loss of Oct4 expression. Scale
bar in (A) corresponds to 500 mm in (A) (left panel), 50 mm in (A) (right panel), and 100 mm in (C) (lower panels) and in (E).analysis, nucleiwereseparated fromeachother and cells weredis-
tributed evenly over the area of each well without forming multilay-
ered structures (Figures 1C–1E). The density was also suitable to
withstand repeated wash cycles required for our immunostaining
protocol at the time of analysis.
Increase and decrease in the expression of the pluripotency
factor Oct4 was used as primary readout. FGF2 supplementationwas withdrawn from hESC cultures at day 2 after plating. Contin-
ued exposure to FGF2 until day 7 resulted in high Oct4 levels de-
fined as high control (promoting self-renewal), while FGF2 with-
drawal resulted in a sensitized state amenable to readout both
self-renewal and differentiation compounds. Treatment with
BMP4 induced a dramatic decrease in Oct4 expression, which
was defined as low control (induction of differentiation) in ourCell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc. 603
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(A) (Upper panel) Out of 89 compounds identified in the primary screen, 65 compounds were subjected to further dose-response analysis resulting in 22 con-
firmed hits. (Lower panel) Representative images illustrating effects of activator, inhibitor, and cytotoxic compounds. Scale bar corresponds to 80 mm.
(B) Dose-response curves for a selected set of activators (left panel) and inhibitors (right panel). Data are expressed as Oct4 ratio of FGF2 versus BMP4-treated
cells with FGF2 levels arbitrarily set at 100%. Levels of BMP4 and FGF2 treatment are marked in graph by dotted lines at 0% and 100%, respectively.
(C) The 22 chemicals with dose-dependent effects on hESC fate could be grouped into several categories based on current clinical drug indications of the com-
pounds. Significant enrichment in hit list compared to library composition was observed for the categories cardiac glycosides (p < 0.000001) and antiinflamma-
tory compounds (p < 0.05).assay (Figure 1C). HESCs were exposed to the chemicals from
days 2 to 7 (Figure 1D). Growth in conditioned medium (CM) for
48 hr prior to exposure to compounds provided sufficient time
for dissociated hESCs to recover from the dissociation procedure
and resume growth. The medium change at 48 hr after plating al-
lowed removal of nonattached and dead cells. Compounds were
diluted in KSR medium at a final concentration of 10 mM and
added to the cells. Cells were assayed at day 7 (5 days/120 hr af-
ter exposure to the compounds) via high-throughput laser-scan-
ning confocal microscopy (GE InCell Analyzer 3000) following au-
tomated immunocytochemistry. Oct4 levels were normalized to
nuclear Hoechst 33342 staining in order to control for effects of
the compounds on total cell number (Figure 1D), and z0 values
were calculated to establish statistical robustness of the assay
(Figure S3). To probe the validity of the 384-well assay, we tested
a number of additional compounds with known activities in
hESCs (Figure 1E) including IGF2 (Bendall et al., 2007), BMP2
(Pera et al., 2004), and PD98059 (Li et al., 2007). While our primary
screen was carried out in H9 cells (WA-09), the conditions for sin-
gle-cell dissociation, 384-well plating, and validations for high
and low controls were fully reproduced in an independent hESC
line (H1, WA-01; Figure S4).
Assay Validation and Primary Screen for Compounds
Promoting hESC Self-Renewal and Differentiation
Using this assay, we screened a library of 2880 small molecules
in multiple replicates. The library contained a broad set of biolog-
ically active and structurally diverse compounds including a set
of 748 currently marketed drugs (for details, see the Experimen-
tal Procedures and Antczak et al. [2007]). Compounds were604 Cell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc.screened at a final concentration of 10 mM in a volume of 50 ml
per well containing 1% DMSO (v/v). Normalized Oct4 values
for each of the replicate 384-well plates were ranked and ana-
lyzed for repeated low or high hits. Out of the 89 hits (3% of
total molecules screened), 65 compounds were selected for
subsequent dose-response assays based on their repeated
high or low values in Oct4 expression intensity. A total of 22 com-
pounds exhibited dose-dependent effects on normalized Oct4
values. Exposure to four of the compounds resulted in increased
Oct4 intensity (activators), while ten compounds caused a de-
crease in Oct4 intensity (inhibitors) (Figure 2A). The remaining
eight compounds showed dose-dependent toxicity in our assay
without inducing differentiation (cytotoxic). A list of all 22 com-
pounds is provided in Table S1. Representative images for
each of the three responses (self-renewal, differentiation, cell
death) are shown in Figure 2A, lower panel. Dose-response
curves demonstrated that several activators induced Oct4 levels
comparable to or higher than those achieved by FGF2 treatment.
Similarly, several inhibitors led to a decrease in Oct4 levels com-
parable to BMP4 treatment (Figure 2B). Several classes of drugs
were represented multiple times within the list of 22 confirmed
hits, such as antiinflammatory drugs, antibiotics, and cardiac
glycosides (Figure 2C). A significant overrepresentation of com-
pounds in cardiac glycoside and antiinflammatory compound
categories was observed compared with overall library compo-
sition: cardiac glycosides, 18% of confirmed hits, < 0.1% of
library, p < 0.000001; antiinflammatory compounds, 14% of con-
firmed hits, 4% of library, p < 0.05 ; antibiotics, 18% of con-
firmed hits, < 10% of library, p not significant. Chemical identity
was confirmed by mass spectrometry (data not shown).
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(A) Expression of Oct4 and Nanog upon treatment with the four activator compounds was confirmed in H9 and in H1 hESCs.
(B) Repeated passaging of hESCs (H9) showed an increase in the percentage of undifferentiated colonies in presence of the self-renewal drugs, compared to HES
medium alone (Ø). The graph represents the relative increase of undifferentiated colonies comparing HES medium alone (defined as 0%) versus MEF-CM
supplemented with FGF2 (defined as 100%). Drug effects were tested at 50 and 100 mm as indicated.
(C) Mouse ESC self-renewal was tested after three passages using an Oct4::eGFP BAC transgenic mouse ESC line. The percentage of eGFP+ cells was quan-
tified by flow cytometry, and the levels of Oct4 cells achieved in mouse ESC medium alone (defined as Ø = 0%) were compared to those treated with LIF (defined
as 100%). Drug effects were tested at 10 and 100 mM as indicated.
(D) Quantification of the ratio of Oct4/DAPI staining under different culture conditions. Data are presented as mean ± SEM. Statistical analysis with ANOVA and
post hoc Dunnett’s test showed that the BMP4 group was significantly different from HES control (p < 0.001), while none of the other treatments were significantly
different from control.
(E) Representative images of Oct4 immunoreactivity in hESCs maintained with CM, FBP, THEA, and BMP4 over two passages. Note that BMP4 causes a rapid
downregulation of Oct4.
(F) Cell-cycle data for hESCs maintained with the self-renewal drugs or controls over two passages.Secondary Assays Define Compounds with Effects
on Oct4 Expression and Short-Term Self-Renewal
in Human and Mouse ESCs
Activator compounds were subjected to a number of biological
validations. Effects on Oct4 were confirmed using Nanog expres-
sion as an alternative pluripotency marker and using H1 as an ad-
ditional hESC line. All four activator compounds, theanine (THEA),
sinomenine (SNM), gatifloxacin (GTFX), and flurbiprofen (FBP) in-duced expression of Nanog at levels comparable to Oct4 in both
H9 and H1 (Figure 3A). Maintenance of hESCs on Matrigel in the
presence of these activators was tested in a basic hESC medium
(Perrier et al., 2004) that lacked FGF2 supplementation and con-
ditioning in mouse embryonic fibroblasts (MEFs). The number of
undifferentiated colonies was quantified after multiple passages
in vitro. We observed that each of the four activator compounds
yielded a strong increase in the percentage of undifferentiatedCell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc. 605
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The efficiency of these drugs in maintaining colonies undifferen-
tiated was comparable to FGF2 exposure, though it did not reach
the levels achieved by combined MEF conditioning and FGF2
supplementation of the medium (Figure 3B).
While key transcriptional regulators of pluripotency are shared
between human and mouse ES cells, extrinsic conditions re-
quired to maintain an undifferentiated state are quite distinct.
Here we tested whether the four activator compounds identified
in our primary hESC based screen are capable of promoting self-
renewal in mouse ES cells. To this end, an Oct4::eGFP line was
generated by BAC transgenesis (Figure S5) following our previ-
ously published protocols (Tomishima et al., 2007). Using
FACS analysis, we observed a dose-dependent effect of GTFX
on Oct4 expression that was comparable to the effect of LIF
treatment. Treatment with FBP or SNM resulted in a dose-
dependent partial effect, while supplementation with THEA did
not increase Oct4 expression in mouse ESCs (Figure 3C). We
next assessed Oct4 expression in hESC cultures following initial
exposure and subsequent passaging of cells under standard 6-
well culture conditions. Oct4/DAPI ratio was determined follow-
ing immunocytochemistry and quantitative imaging (ImageJ, for
details see the Experimental Procedures). These data confirmed
a near-complete loss of Oct4 in BMP4-treated cultures and
maintenance of Oct4 expression in control, compound, and
FGF2 treated cultures (Figures 3D and 3E). To further explore
the impact of compound treatment on hESC growth, we per-
formed cell-cycle analysis via flow cytometry using cells loading
with propidium iodide-citrate solution (Figure 3F; for details, see
the Experimental Procedures; Figure S6). The cell-cycle data
showed that FGF2 treatment results in a high percentage of cells
in S or G2/M phase, indicating a high degree of cell division at
both passages (1 and 2). In contrast, exposure to BMP4 led to
a marked increase in the proportion of cells in G1/G0 compatible
with an increase in cell differentiation at passage 2. Drug-treated
cells showed a high proportion of cells in S and G2/M phase,
similar to IGF treatment. Cultures maintained under control
conditions (Ø) yielded an increased proportion of cells at G1/G0
in passage 2.
A next set of studies addressed apoptotic cell death and main-
tenance of pluripotency in compound-treated hESC cultures.
We observed low overall percentages of TUNEL+ cells at day 4
upon compound exposure without significant differences among
the various treatment groups (Figure 4A). Directed differentiation
assays toward neurectoderm (Perrier et al., 2004), endoderm
(Watanabe et al., 2007), and mesoderm (Laflamme et al., 2007)
fate showed that differentiation potential toward all three germ
layers was retained (Figure 4B). However, long-term mainte-
nance revealed that the drugs were not capable of reproducing
the full effect of CM. Spontaneous differentiation under feeder-
free conditions upon long-term passaging was eventually ob-
served in all conditions, even when combining multiple com-
pounds (data not shown).
Global mRNA expression analysis identified a total of >1000
transcripts (Table S2; Experimental Procedures) significantly
regulated after drug treatment compared to basal hESC medium
(without FGF2 or MEF conditioning). Gene expression analysis
was performed immediately upon exposure to drugs (24 hr). At
that stage of culture, we did not observe any signs of differenti-606 Cell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc.ation or cell heterogeneity. A heat map of the changes showed
coregulation for many of the mRNAs induced by drug treatment
with those induced by CM or CM supplemented with FGF2
(Figure 4C). Both SNM and GTFX showed highly significant over-
laps in gene expression with CM treatment (p < 109) and with
combined CM + FGF2 treatment (p < 1016) (Figures 4D and
4E). Functional annotation of the most differentially regulated
transcripts using DAVID, http://david.abcc.ncifcrf.gov (Dennis
et al., 2003), confirmed strong regulation of TGF-b and Wnt sig-
naling pathways in cultures treated with CM. However, despite
significant overlap in overall analysis (Figures 4D and 4E), the
top most differentially regulated categories in GTFX- or SNM-
treated cultures were distinct (Figure 4F, Table S3). Regulation
of heparin binding in GTFX-treated cultures could potentiate en-
dogenous FGF signaling in hESC cultures. Fibronectin-1 that
was significantly regulated in SNM-treated cultures has been
a key component in a novel serum- and feeder-free culture sys-
tem proposed for hESC maintenance (Amit and Itskovitz-Eldor,
2006). However, future studies will have to directly address the
contribution of these individual candidate pathways in mediating
the self-renewal-promoting response of each compound.
Interestingly, a chemical derivative of GTFX, orbifloxacin, had
comparable effects on Oct4 maintenance, while another closely
related compound, ciprofloxacin, lacked Oct4-inducing activi-
ties and caused differentiation toward mesendodermal fates
(Figure S7). Similarly, we identified a derivative of FBP, felbinac,
capable of promoting maintenance of Oct4 (Figure S7). The
availability of related compounds with distinct action on hESC
differentiation will provide an entry point toward structure-func-
tion studies and an understanding of mechanism of action.
These data demonstrate that our HTS assay is suitable for the
identification of compounds promoting hESC self-renewal and
that several of these compounds fall into the category of cur-
rently marketed drugs (GTFX, SNM, and FBP) or natural com-
pounds such as THEA found in black tea. The fact that none of
the activators was sufficient to induce long-term self-renewal
indicates the need for screening larger libraries and further mod-
ifications in screening design. One promising strategy may
be the use of larger primary screens followed by stringent sec-
ondary assays measuring long-term hESC self-renewal more
directly.
Induction of Distinct Lineage-SpecificMarkers in hESCs
Exposed to Small Molecules Inhibiting Oct4 Expression
We next tested the function of a selected set of four out of ten in-
hibitor compounds including tretinoin (all-trans retinoic acid, RA),
selegiline (SLG), cymarin (CYM), and sarmentogenin (SRM) that
induced a dose-dependent reduction in Oct4 levels (Figure 5A).
We first validated the effect of these drugs on loss of pluripotency
using Nanog as an alternative marker in WA-09 and confirmed
loss of both Oct4 and Nanog in H1 (Figure 5A). We hypothesized
that loss of Oct4 expression in our high-content assay can be
used as a surrogate marker for the identification of compounds
that induce early differentiation events in hESCs. Key lineage
choices accessible to undifferentiated hESCs include extraem-
bryonic fates such as trophoblast (Xu et al., 2002) or primitive en-
doderm differentiation (Pera et al., 2004), mesendodermal (Bar-
beri et al., 2007; D’Amour et al., 2005), and ectodermal fates
(Zhang et al., 2001). A selected repertoire of these fate choices
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(A) TUNEL analysis of hESCs maintained in the presence of various compounds and under control conditions did not reveal significant differences among groups.
Data are presented as mean ± SEM.
(B) Pluripotency was assessed using directed differentiation protocols in hESCs maintained for three passages in the presence of compounds or control
conditions.
(C) Total of 1,145 transcripts out of 22,177 transcripts were differentially expressed during treatments of hESCs with CM, CM + bFGF, or self-renewal drugs
compared to basal hESC medium alone. These genes were clustered, and a heat map for all conditions in duplicate or triplicates was established.
(D) Venn diagram showing the number of transcripts differentially expressed in GTFX-treated cells or cells maintained in MEF-CM or in MEF-CM supplemented
with FGF2 (CM + FGF2) versus cells maintained in basic hESC medium. Significance of overlap in GTFX versus CM was p < 1010; GTXF versus CM + FGF2 was
p < 1016.
(E) Venn diagram showing the number of transcripts differentially expressed in SNM-treated cells using the same parameters as in (D). Significance of overlap in
SNM versus CM was p < 1010 and p < 1016 versus CM + FGF2.
(F) Functional annotation analysis using DAVID platform (http://david.abcc.ncifcrf.gov; Dennis et al., 2003) illustrates overrepresentation of transcript categories
within a given treatment group compared to control cultures. Significance and relative fold levels of enrichment are presented. Full description of the algorithms
used, the definition of the categories, and list of all transcript members included per category are provided in Table S3 and in the Experimental Procedures.was assessed at the time of Oct4 analysis by automated immuno-
cytochemistry for cytokeratin 18 (CK18, trophoblast marker),
Sox17 (mesendoderm/endoderm), and Pax6 (neuroectoderm).
We observed that exposure to tretinoin induced CK18 at levels
comparable to BMP4 treatment. Exposure to the cardiac glyco-sides (CYM or SARM) caused an increase in Sox17 expression
(Figure 5B). Quantification of the percentage of Sox17+ cells (Fig-
ures 5C and 5D) was compatible with the Sox17 signal intensity
data in Figure 5B. Both CYM and SARM yielded an increase
in the percentage of Sox17+ cells comparable to the effectCell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc. 607
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(A) Expression of Oct4 was downregulated upon treatment with inhibitor compounds (left panels). Markers of differentiation were used to characterize lineage
choice promoted by a given compound. Tretinoin (RA) showed strong induction of cytokeratin 18 (CK18), selegiline increased expression of Pax6 over time, and
cymarin and sarmentogenin showed induction of Sox17 (right panels). These effects were established in the hESC line H9 and confirmed in H1.
(B) (Upper panel) CK18 intensity signal was quantified using the confocal InCell Analyzer 3000 at day 7 of assay. (Lower panel) Under the same conditions,
expression of Sox17 was quantified. Data are presented as mean ± SEM. Statistical significance was defined as: *p < 0.05, **p < 0.01, ***p < 0.001, ANOVA
followed by Dunnett’s test.
(C) Percentage of Sox17+ cells under control conditions or in the presence of CYM, SRM, or ActivinA (positive control).
(D) Representative images of Sox17 immunocytochemistry at the time of analysis used for quantification in (C). Scale bar in (D) corresponds to 10 mm.observed upon ActivinA exposure. While SLG did not show any
significant increase in the percentage of cells expressing differen-
tiation markers at day 7 of differentiation, an increased number of
Pax6+ clusters in longer term cultures is compatible with recent
observations in mouse ES cells (Esmaeili et al., 2006).
Global gene expression analysis 24 hr after drug exposure
(Figure 6A) confirmed a large number of differentially expressed
transcripts (Table S4) that are significantly coregulated in CYM-
and SRM-treated cultures (Figure 6B; p < 10241). A large num-
ber of these transcripts were compatible with early differentiation
events toward mesendodermal lineage choice. In contrast, ex-
posure to tretinoin (RA) treatment led to an upregulation of genes
compatible with extraembryonic and neuroectodermal differen-
tiation (Figure 6C, Table S4), while transcripts induced by SLG
treatment were most compatible with neurectodermal and neu-
ral crest differentiation (Figure S8). Functional annotation analy-
sis (DAVID, http://david.abcc.ncifcrf.gov/; Dennis et al., 2003) in
RA-treated cultures demonstrated enrichment in categories
known to be associated with retinoid signaling including regula-
tion of Hox genes, modulation of Id2 repressor, and other bHLH-
related factors (Figure 6D). SLG exposure showed significant
enrichment in transcripts associated with signaling and cell
differentiation. SRM and CYM exposure showed enrichment in
the regulation of highly overlapping sets of functional category
terms including lipoprotein, basic leucin zipper, and various
categories associated with development and differentiation
(Figure 6D, Table S5).
DISCUSSION
Our data demonstrate the feasibility of performing a primary HTS
assay in hESCs and pave the way for establishing high-content
screening platforms ranging from assays that address questions
in basic hESC biology to translational applications and drug dis-608 Cell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc.covery. The design of our primary HTS assay is suited for the
screening of large compound libraries. The significant costs of
such an effort may be offset by the identification of compounds
promoting self-renewal as well as compounds driving differenti-
ation. Putative differentiation compounds identified in the pri-
mary screen can be subsequently classified into compound
classes promoting various lineage-specific cell fates using sec-
ondary screens. However, it will be critical in the future to fully
validate all secondary screens using z0 analysis up to the stan-
dards of a primary screen. Our current assay requires high initial
plating densities to compensate for cell loss at the time of plating
and to assure even cell distribution throughout the surface area
of each well. At this cell density, we did not observe stacking of
multiple nuclei that would prevent reliable image analysis. One
disadvantage of using such high cell densities is the relatively
large number of total cells needed for a full-scale HTS screen.
For example, screening a library of 1 million compounds without
replicates but including internal high and low controls will require
6 3 109 cells. Future studies should allow primary HTS assays
in hESCs at lower cell densities by reducing initial cell death at
plating. One interesting compound to be tested is the ROCK in-
hibitor Y-27632, shown to increase efficiency of plating dissoci-
ated hESCs at low cell densities (Watanabe et al., 2007).
There is currently a very limited set of chemical compounds
available that affect hESC behavior (Chen et al., 2006; Ding
et al., 2003; Sato et al., 2004), and none of these compounds
have been identified through primary HTS assays in hESCs.
The newly discovered compounds enhance our repertoire
of chemical modulators suitable for directing growth and differ-
entiation of hESCs. Future studies will have to explore the
mechanistic action of these compounds on the self-renewal
and differentiation machinery of hESCs. Our gene expression
data, functional annotation analysis, and data from the literature
on drug action of several of these compounds will provide
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(A) A total of 6163 transcripts were differentially expressed during treatments of hESCs with KSR+DMSO or treatment with any of the inhibitor compounds com-
pared with cells maintained in KSR medium alone. These genes were clustered, and a heat map for all conditions in duplicate or triplicates was established.
(B) Venn diagram showing the number of transcripts differentially expressed in sarmentogenin (SRM), cymarin (CYM), or tretinoin (RA) versus cells maintained in
KSR only.
(C) The top ten upregulated and top five downregulated genes out of the total set of 22,177 transcripts are listed for the three drugs. Six out of the ten most
regulated transcripts in CYM and SRM are identical.
(D) Functional annotation analysis using DAVID platform (http://david.abcc.ncifcrf.gov/; Dennis et al., 2003) illustrates overrepresentation of transcript categories
within a given treatment group compared to control cultures. Significance and relative fold levels of enrichment are presented. Full description of the algorithms
used, the definition of the categories, and a list of all transcript members included per category are provided in Table S5 and in the Experimental Procedures.valuable entry points to this end. One issue to be addressed is
whether any given compound works directly on undifferentiated
hESCs or whether such an effect could be due to a bystander
effect mediated by hESC-derived differentiated progeny. Such
a bystander effect could feed back on undifferentiated hESCs
as proposed in the case of spontaneously emerging hESC-de-
rived fibroblast (Bendall et al., 2007). The lack of true long-term
self-renewal factors among the activator compounds identified
in the current study suggests that such molecules may be rare
and require the screening of much larger libraries. Another criti-
cal question is whether the induction of Sox17 observed upon
exposure to CYM and SRM can be translated into a protocol
for generating endodermal derivatives from hESCs. While the
percentage of Sox17+ cells was increased at levels comparable
or higher than those achieved by ActivinA, CYM and SRM had
a negative effect on overall cell growth. Future studies will
have to address this issue in more detail by systematically map-
ping the expression of endodermal genes and cell fates in the
presence of these compounds.
Several of the cytotoxic factors identified here (Figure 2A, Table
S1) could be further explored for the selective elimination of undif-
ferentiated hESCs intermixed in hESC progeny prior to transplan-
tation and as a paradigm for cell-toxicity studies. In addition, one
direct application for such assays could be the identification of
compounds with teratogenic potential. Differentiation of self-
renewal promoting effects at the hESC stage may reflect the po-tential for similar effects during early human embryonic develop-
ment in vivo. The identification of retinoic acid, a well-known ter-
atogenic compound in our study, supports this hypothesis. The
emergence of national HTS centers such as the ten centers
established through the National Institutes of Health (NIH) Road-
map Initiative http://mli.nih.gov/mli/mlscn/screening-centers/
and additional centers sponsored by state initiatives in the U.S.
and multinational initiatives in Europe and Asia should provide
access to HTS technology more readily. This will be particularly
important for users in the stem cell field that do not have access
to individual screening centers at their own institutions. Once an
HTS assay has been optimized for use, which represents the lon-
gest step, the actual screening process is quite rapid. The cell
numbers required for our assay (50–1003 106 cells) can be gen-
erated starting from a single 6 cm plate of hESCs in approximately
4 weeks. From the time of plating to full data analysis of a 2880
compound library, the screen can be completed in less than 2
weeks. There was an overall failure rate of about one in three as-
says defined as not reaching acceptable standards in positive
and negative controls that are included on every plate (value
not comparable to original z0). This relatively large failure rate
was caused mainly by the variability in the quality of undifferenti-
ated hESCs maintained in bulk cultures. Future improvements in
large-scale hESC culturing should help reduce failure rates.
In conclusion, our data demonstrate the feasibility of perform-
ing primary HTS assays in hESCs. Our screen resulted in theCell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc. 609
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The use of HTS assays should dramatically enhance our under-
standing of hESC biology and facilitate the application of hESCs
in drug development and cell therapy.
EXPERIMENTAL PROCEDURES
Human ES Cell Culture and 384-Well Plating
The hESC lines H9 (WA-09, passages 35–45) and H1 (WA-01, passages
30–45) were used for this study. HESCs were cultured on mitotically inacti-
vated MEFs as described previously (Perrier et al., 2004) followed by feeder-
free growth on Matrigel in MEF-CM (Xu et al., 2001) prior to 384-well plating.
For 384-well plating, cells were harvested following Accutase dissociation for
20 min at 37C. At that stage, single-cell suspensions could be obtained with-
out further mechanical dissociation, and dissociated cells displayed high levels
of viability (>95% based on trypan exclusion). hESCs were plated at 6000 cells
per well from a stirred single-cell suspension (typically 50–100 3 106 cells
per experiment) in MEF-conditioned hESC medium using a Multidrop Dis-
penser (Thermo). Quality control (QC) steps were added with each set of
experiments using Alamar blue assay. For the assay, the dye resazurin was
added to living hESCs at 5 mM according to the specification of the manufac-
turer, and fluorescence was measured 24 hr later, providing a quantitative
estimate of the number of metabolically active cells. At the time of the assay
(day 2 of assay), KSR medium (Perrier et al., 2004) was added to the plates
of compounds diluted in 100% DMSO, and the KSR-diluted compounds
were transferred to the hESC plates at 10 mM final concentration in 1%
DMSO (v/v). The cells were maintained in compounds until day 7. DMSO is
the preferred solvent for chemical libraries because of its stability and low-tem-
perature flash point, making it amenable for use with robotic liquid handling
systems. To address potential interference of DMSO with hESC self-renewal,
we demonstrated robust long-term maintenance of undifferentiated hESCs
in the presence of 1% DMSO when using CM + FGF2 (10 ng/ml). These studies
were based on measuring expression of pluripotency markers (Oct4, SSEA3),
cell-cycle analysis, and percentage of undifferentiated colonies over a period
of 5–10 passages (data not shown).
Every 384-well plate in the screen included 16 wells each for high and for low
internal controls. FGF2 (R&D Systems) was supplemented at 200 ng/ml (Lev-
enstein et al., 2006) in high control wells (promoting self-renewal). BMP4 (R&D
Systems) was added at 200 ng/ml in low control wells (induction of differenti-
ation). These concentrations were selected based on dose titration assays for
high and low Oct4 signal under HTS conditions, taking into account stability
and degradation pattern of the factors (data not shown). Additional control
treatments were used to demonstrate the robustness of the assay: IGF
(30 ng/ml, R&D Systems), BMP2 (100 ng/ml, R&D Systems), and PD98059
(50 mM, Tocris Bioscience).
Immunohistochemistry, Automation, and Image Analysis
Fixation in 4% paraformaldehyde/0.15% picric acid was followed by standard
fluorescent immunocytochemical techniques using the following primary anti-
bodies: monoclonal, BrdU (Sigma) and Oct4 (Santa-Cruz); and polyclonal,
Nanog (R&D Systems), Sox17 (R&D Systems), CK18 (Santa-Cruz), and Pax6
(Covance). All stainings were adapted for 384-well plates for automation. Liq-
uid-handling systems were used to aspirate and dispense liquid from and in
384-well plates. Aspirations were performed using a Multidrop 384 (Thermo,
Electron Corporation, Waltham, MA). Dispensions of fluids were performed
using either the Multidrop 384, for rinsing steps, or a Flexdrop IV (PerkinElmer,
Waltham, MA) for Matrigel (BD Biosciences, San Jose, CA), cell plating, and
antibody staining. Compounds were transferred on cells using a TPS-384 total
pipetting platform (Apricot). Confocal image acquisition was carried out with
an InCell Analyzer 3000 (GE Healthcare). An average of four images per well
were collected, two images at 488 nm and two images for Hoechst 33342, us-
ing a 103 objective. Data analysis was performed using the InCell Investigator
software. Images were first processed by a flat-field correction. The object
intensity analysis module from the InCell Investigator software (GE Healthcare,
USA) was used to measure the signal intensity of objects in the defined mea-
surement region. The algorithm first identified the nucleus in the marker chan-
nel and then quantified the signal region within the area of the nucleus. Aver-610 Cell Stem Cell 2, 602–612, June 2008 ª2008 Elsevier Inc.age signal intensity was calculated by measuring total intensity divided by the
number of objects (i.e., cells) and expressed as arbitrary units (AU). Screening
data files obtained from the Amersham InCell Investigator software postpro-
cessing were loaded into the HTS Core Screening Data Management System
(Antczak et al., 2007). Hits were defined as the repeated top ranked com-
pounds per plate that also exhibited at least a >30% increase (inducing com-
pounds) or >30% decrease (inhibitory compounds) in normalized Oct4 values
in R2 independent runs in duplicates. Data for some compounds data were
confirmed in up to six independent runs.
Validation Studies
Self-Renewal Compounds
The effect was tested over multiple passages on undifferentiated H9 hESCs
passaged using a standard dispase (Worthington Biochemical Corp., Lake-
wood, NJ) protocol (Perrier et al., 2004) under feeder-free conditions on Ma-
trigel in the presence of MEF-CM and FGF2 (10 ng/ml). Two days after plating,
CM was replaced with HES medium containing THEA (50 mM), SNM (50 mM),
FBP (25 mM), or GTFX (50 mM). Control conditions were matched with regard
to DMSO concentration. At each passage, cells were dissociated with Accu-
tase and subjected to cycle analysis by FACS after propidium iodide-citrate
solution treatment (50 mg/ml propidium iodide, 0.1% sodium citrate dihydrate,
200 mg/ml RNaseA, and 0.1% Triton X-100). In brief, 2 3 105-dissociated
hESCs were washed once with PBS, incubated with propidium iodide-citrate
solution for 10 min in the dark, and analyzed. FACS analysis was performed
on a FACSCalibur system (BD Biosciences). For Oct4/DAPI ratio quantifica-
tion, cells were subjected to Oct4 immunocytochemistry, and four 0.15 mm2
microscopic fields were imaged and analyzed using ImageJ software (NIH,
Bethesda, MD). In brief, Oct4 and DAPI channels were subjected to thresh-
olding independently, the stain surface area was measured, and finally the
ratio of the surface areas was calculated. Apoptotic cell death was quantified
after plating of H9 hESCs on Matrigel in CM + FGF2 (10 ng/ml) for 2 days fol-
lowed by 4 days of drug treatment and subjection to fixation and TUNEL
assay (Roche Diagnostics Corporation, Indianapolis, IN). The percentage of
TUNEL+ cells was quantified in uniform randomly selected fields of 0.15 mm2
(n = 5 per group) together with DAPI for ratio measurement. Pluripotency
was assessed by directed differentiation of H9 maintained over three pas-
sages in the presence of self-renewal compounds. For endoderm induction,
hESCs were treated with ActivinA (100 ng/ml) for 6 days in DMEM/F12 me-
dium containing 1% FBS (Invitrogen, Carlsbad, CA) as previously described
(Watanabe et al., 2007). For mesoderm induction, cells were cultured in
RPMI medium supplemented with B27 (Invitrogen) as previously reported
(Laflamme et al., 2007). In brief, ActivinA (100 ng/ml; R&D Systems) was
added for 1 day, followed by BMP4 (10 ng/ml) for an additional next 4 days.
After withdrawal of BMP4, cells were maintained in RPMI-B27 medium for
12 days before staining. Neuroectoderm induction was achieved using a co-
culture system (Perrier et al., 2004) in which hESCs are plated on stromal
cells (MS5) in the presence of Noggin (250 ng/ml) added starting at day 3
of differentiation. Immunofluorescence analysis was performed at day 12 of
differentiation. The following antibodies were used: Sox17 for endoderm
induction, smooth muscle actin (SMA, Sigma) for mesodermal differentiation,
and Pax6 (Covance) for neuroectoderm induction.
Differentiation Compounds
hESCs were plated in 384-well plates following the described HTS protocol.
Each condition (untreated medium Ø, BMP4, RA, SLG, CYM, SRM, or Acti-
vinA) had six replicates for each staining (CK18 or Sox17). Four images per
well were captured by InCell 3000 scanner and quantified for intensity signal
measurements. Percentages of Sox17+ cells were quantified by computer-
assisted analysis using ImageJ with automated thresholding as described
above. All data were normalized to Hoechst (intensity signal) or DAPI (percent-
age of Sox17+ cells).
Chemical Libraries
The library used for the current study combines chemicals obtained commer-
cially from Prestwick and MicroSource. The MicroSource library (http://www.
msdiscovery.com/) contains 2000 biologically active and structurally diverse
compounds from known drugs, experimental bioactives, and pure natural
products. The library includes a collection of 720 natural products and their
derivatives, a range of simple and complex oxygen-containing heterocycles,
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many other diverse representatives. The Prestwick Chemical Library (http://
www.prestwickchemical.fr/) is a collection of 880 high-purity chemical com-
pounds selected for structural diversity and representing drug classes with
a broad spectrum of therapeutic uses. More than 85% of its compounds are
marketed drugs.
Statistical Analysis of HTS Assay and Dose-Response Study
To assess the performance of the assay, the z0 factor value was determined.
This factor represents a dimensionless parameter, which value can range be-
tween <0 and 1. It is defined as 1  z0 = (3sc+ + 3sc–)/jmc+  mc–j, where sc+,
sc–,mc+, andmc– are the standard deviations (s) and averages (m) of the high (c+)
and low (c–) controls (Zhang et al., 1999). To obtain this value, three 384 plates of
high control (1% DMSO + FGF2) and low controls (1% DMSO + BMP4) were
analyzed (Figure S3). For dose-response analysis, each 384-well plate of
exposed to hits from the primary screen contained replicate wells for high
and low controls. Each concentration was applied in duplicates over a range
of 12 different doubling dilutions between 0 and 100 mM.
Microarray Analysis
RNA was isolated (QIAGEN), labeled, and prepared for Illumina bead arrays
following the instructions of the manufacturer (SKI Genomics Core Facility).
All data were analyzed using the Bioconductor packages (http://www.
bioconductor.com/) for the R statistical system. The arrays were quantitated
using the Illumina BeadStudio program, and raw data (normalized and non-
background subtracted signal levels) were exported. Normalization was car-
ried out using the quantile method for the AFFT Bioconductor package. Probes
that had detection p values >0.01 in 75% or more samples were removed as
noise. Expression signal levels were then log 2 transformed. To determine
genes that are differentially expressed between the various sample types,
the LIMMA package was used. This performs a variant of linear models
(t test or ANOVA) in which the variance is corrected to deal with small sample
numbers. To account for the multitesting issue, the false discovery rate (FDR)
method was used with cutoffs of 0.20 for the HES samples comparison (self-
renewal factors) and 0.05 for the KSR sample comparison (differentiation
factors). To determine the significance of overlaps between different gene
sets, the standard Fisher’s test (hypergeometric distribution) was performed.
Functional annotation analysis was performed using the DAVID platform
(DAVID, http://david.abcc.ncifcrf.gov/ [Dennis et al., 2003]). A list of differen-
tially regulated transcripts for a given compound was established at the FDR
levels described above. For analysis, we selected only transcripts with a fold
change of R2 compared with control. For those compounds with less than
200 differential transcripts at a fold change level of 2, the analysis was
extended to those with a fold change of R1.5. Final selection of categories
for presentation eliminated duplicate categories that contained identical
gene lists. Furthermore, all included terms exhibited significant p values for en-
richment and generally contained greater than two members per category.
ACCESSION NUMBERS
All raw data are available online under Gene Omnibus (GEO) accession
number GSE11302.
SUPPLEMENTAL DATA
Supplemental Data include eight figures and can be found with this article
online at http://www.cellstemcell.com/cgi/content/full/2/6/602/DC1/.
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